Treatment of non-high-risk acute promyelocytic leukemia with realgar-indigo naturalis formula (RIF) and all-trans retinoid acid (ATRA): study protocol for a randomized controlled trial

BACKGROUND: Acute promyelocytic leukemia (APL) is a highly curable disease when treated with all-trans retinoid acid (ATRA) and arsenic trioxide (ATO). The combination of ATO and ATRA has become the standard therapeutic protocol for induction therapy in non-high-risk APL. An oral arsenic realgar-ind...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhang, Xinxin, Liu, Li, Yao, Yazhou, Gong, Sha, Wang, Mengchang, Xi, Jieying, Chen, Limei, Wei, Suhua, Zhang, Huiyun, Zhao, Chenyang, Wang, Huaiyu
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2020
Materias:
Study Protocol
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6941314/
https://www.ncbi.nlm.nih.gov/pubmed/31898521
http://dx.doi.org/10.1186/s13063-019-3983-2

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6941314/
https://www.ncbi.nlm.nih.gov/pubmed/31898521
http://dx.doi.org/10.1186/s13063-019-3983-2

Ejemplares similares